Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)

The overarching goal of this NIDA Notice of Funding Opportunity (NOFO) is to elucidate and validate the molecular, cellular, circuitry and structural mechanisms and pathways that underly the pharmacology of psychedelic compounds for treating substance use disorders (SUDs) and related psychiatric and neurological co-morbidities. This NOFO will also support the design and synthesis of chemical probes to provide mechanistic insights on biological targets modulated by psychedelics, and on common targets/pathways in the context of SUD. Research supported via this NIDA NOFO should facilitate transformative advances within the field that would primarily impact the activities of addictive drugs and/or addiction-relevant phenotypes.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.